Notice Type
Departmental
Notice Title

Notice of Application to Vary the Conditions of a Registered Trade Name Product (Notice No. MPI 667)

Maree Zinzley, Manager Approvals Operations of the Ministry for Primary Industries (MPI), acting under delegated authority from the Director-General of MPI, gives notice, under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”), that the following variation application has been made to a registered trade name product under section 9(2) of the Act:

Trade Name: Bravecto Spot-On Solution

Reference: A011261

Active Ingredient and Concentration:

Fluralaner 280mg/mL

Formulation Type: Vapour releasing product

General Use Claim:

Control of tick and flea infestations on dogs.

      • Immediate and persistent flea (Ctenocephalides sp.) killing activity for six months; and

      • immediate and persistent tick (Haemaphysalis Iongicornis) killing activity for four months.

      • Safe for use in breeding, pregnant and lactating dogs.

      • Safe for use in MDR1 breeds.

      • Controls immature stages of fleas and immature tick stages.

      • Part of a treatment strategy for the control of flea allergy dermatitis.

      • Highly effective against fipronil resistant fleas.

Proposed Variation to Conditions:

For the control of flea and tick infestations on dogs.

      • Immediate and persistent flea (Ctenocephalides sp.) killing activity for six months; and

      • immediate and persistent tick (Haemaphysalis longicornis) killing activity for four months.

      • Treatment and control of Otodectes and Sarcoptes spp. mites.

      • Safe for use in breeding, pregnant and lactating dogs.

      • Safe for use in MDR1 breeds.

      • Controls immature stages of fleas and immature tick stages.

      • Part of a treatment strategy for the control of flea allergy dermatitis.

      • Highly effective against fipronil resistant fleas.

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

  1. must state in full the reasons for making the submission; and
  2. may state any decision sought on that application; and
  3. must be received by the director-general no later than 30 working days after the date of notification in the New Zealand Gazette.

Under section 18 of the Act, a copy of every submission will be forwarded to the applicant for the applicant’s information.

The following address is:

  1. where submissions on this application are to be sent; and
  2. where requests for copies of the public information relating to the application can be sent; and
  3. where public information relating to the application can be viewed; and
  4. the director-general’s address for service:

ACVM Group, Ministry for Primary Industries, Pastoral House, 25 The Terrace, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140.

The applicant’s address for service is:

Schering-Plough Animal Health Limited, 33 Whakatiki Street, Upper Hutt 5018. Postal Address: Private Bag 908, Upper Hutt 5140.

Dated at Wellington this 2nd day of August 2016.

MAREE ZINZLEY, Manager Approvals Operations, Ministry for Primary Industries (acting under delegated authority).